Stocks › BMRN
BIOMARIN PHARMACEUTICAL INC
BMRN·Nasdaq·
United States·USD
United States·USD$56.22
-1.32 (-2.29%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
BMRN
BIOMARIN PHARMACEUTICAL INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
BMRNS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of BMRN by members of U.S. Congress · 25 on record
Whale Activity
Position changes in BMRN reported for 2026-06-30 by 15 tracked institutional filers
- Increased4
- New0
- Held0
- Decreased6
- Closed1
- No prior filing4
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 20.4M | $1.17B | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 8.7M | $500.3M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 8.6M | $494.9M | increased |
| VIKING GLOBAL INVESTORS LP | 7.6M | $435.8M | — |
| MILLENNIUM MANAGEMENT LLC | 2.1M | $118.5M | decreased |
| CITADEL ADVISORS LLC | 1.1M | $64.2M | decreased |
| CAPSTONE INVESTMENT ADVISORS, LLC | 62.4M | $60.8M | — |
| Palo Alto Investors LP | 682.8K | $39.1M | — |
| Opti Capital Management, LP | 28.1M | $27.3M | — |
| RENAISSANCE TECHNOLOGIES LLC | 451.9K | $25.9M | decreased |
| Bridgewater Associates, LP | 274.9K | $15.7M | increased |
| BlackRock, Inc. | 11.6M | $11.3M | decreased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by BMRN insiders, by quarter · Form 4
Recent Insider Transactions
4,367 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Davis George EricEVP, Chief Legal Officer | Sale | −17.6K | $66.28 | $1.2M | Sep 2, 2026 | Form 4 ↗ |
| Countouriotis AthenaDirector | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| Walbert Timothy PDirector | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| Ho MaykinDirector | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| HOMBACH ROBERT J.Director | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| Enyedy Mark JDirector | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| Dere Willard HDirector | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| CLARK IAN TDirector | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| Bodem Barbara W.Director | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| ANDERSON ELIZABETH MDirector | Grant / award | +7,490 | $0.00 | $0 | Jun 2, 2026 | Form 4 ↗ |
| Hubbard CristinEVP, Chief Commercial Officer | Tax withholding | −2,318 | $50.20 | $116K | May 20, 2026 | Form 4 ↗ |
| Friberg Gregory REVP, Chief R&D Officer | Sale | −3,281 | $53.85 | $177K | May 7, 2026 | Form 4 ↗ |
| Davis George EricEVP, Chief Legal Officer | Tax withholding | −1,273 | $56.05 | $71K | Mar 18, 2026 | Form 4 ↗ |
| Guyer Charles GregEVP, Chief Technical Officer | Tax withholding | −1,693 | $56.05 | $95K | Mar 17, 2026 | Form 4 ↗ |
| Mueller BrianEVP, Chief Financial Officer | Tax withholding | −2,117 | $56.05 | $119K | Mar 17, 2026 | Form 4 ↗ |
| Hardy AlexanderChief Executive Officer · Director | Tax withholding | −4,252 | $56.05 | $238K | Mar 17, 2026 | Form 4 ↗ |
| Hubbard CristinEVP, Chief Commercial Officer | Tax withholding | −1,245 | $56.05 | $70K | Mar 17, 2026 | Form 4 ↗ |
| Friberg Gregory REVP, Chief R&D Officer | Tax withholding | −1,629 | $56.05 | $91K | Mar 17, 2026 | Form 4 ↗ |
| Hubbard CristinEVP, Chief Commercial Officer | Grant / award | +15.4K | $0.00 | $0 | Mar 16, 2026 | Form 4 ↗ |
| Friberg Gregory REVP, Chief R&D Officer | Grant / award | +19.1K | $0.00 | $0 | Mar 16, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding BMRN · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Dodge & Cox Stock Fund Dodge & Cox Funds | 9.8M | $559.0M | 0.47% | Jun 30, 2026 |
| iShares Core S&P Mid-Cap ETF iShares Trust | 6.6M | $378.5M | 0.30% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 6.1M | $351.4M | 0.02% | Jun 30, 2026 |
| VANGUARD CAPITAL OPPORTUNITY FUND VANGUARD HORIZON FUNDS | 5.2M | $295.7M | 0.90% | Jun 30, 2026 |
| VANGUARD PRIMECAP FUND VANGUARD CHESTER FUNDS | 5.0M | $284.4M | 0.30% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 4.4M | $253.7M | 0.13% | Jun 30, 2026 |
| Capital World Growth & Income Fund | 2.6M | $147.6M | 0.09% | May 31, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 2.6M | $146.1M | 0.31% | Jun 30, 2026 |
| Fidelity Contrafund | 2.5M | $144.7M | 0.08% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.2M | $126.8M | 0.13% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list BMRN's shares (CUSIP 09061G101), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming BIOMARIN PHARMACEUTICAL INC as client
No lobbying filings found naming BIOMARIN PHARMACEUTICAL INC as the client.
Government Contracts
Federal awards to BIOMARIN PHARMACEUTICAL INC · USAspending
No federal contract awards found for BIOMARIN PHARMACEUTICAL INC.
U.S. Patents
Recent USPTO applications naming BIOMARIN PHARMACEUTICAL INC
No USPTO patent applications found for BIOMARIN PHARMACEUTICAL INC.
Annual Financials
From BMRN's 10-K filings · XBRL
No annual XBRL figures on record for BMRN. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in BMRN's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 1.01Material agreementSep 30, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 15, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeSep 14, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 1, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureAug 31, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureAug 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K/A · Items 8.01, 9.01Other eventsJul 13, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07Officer / director change · Shareholder voteJun 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 4, 2026
EDGAR ↗
About BIOMARIN PHARMACEUTICAL INC
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersNOVATO, CA
IncorporatedDE
SEC CIK0001048477 ↗